NanoString Technologies (NanoString Technologies) ROCE % : -67.14% (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is NanoString Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NanoString Technologies's annualized ROCE % for the quarter that ended in Sep. 2023 was -67.14%.

NanoString Technologies ROCE % Historical Data

The historical data trend for NanoString Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoString Technologies ROCE % Chart

NanoString Technologies Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-67.92

-20.01

-26.16

-23.03

-42.03

NanoString Technologies Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial															-40.04	-53.87	-56.41	-68.02	-67.14

NanoString Technologies ROCE % Calculation

NanoString Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-151.691	/	( ( (479.481 - 52.155)	+	(353.412 - 58.86) )	/ 2 )
	=	-151.691	/	( (427.326	+	294.552)	/ 2 )
	=	-151.691	/	360.939
	=	-42.03 %

NanoString Technologies's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-142.252	/	( ( (288.99 - 62.433)	+	(274.713 - 77.532) )	/ 2 )
	=	-142.252	/	( ( 226.557	+	197.181 )	/ 2 )
	=	-142.252	/	211.869
	=	-67.14 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

NanoString Technologies (OTCPK:NSTGQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NanoString Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of NanoString Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

NanoString Technologies (NanoString Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoString Technologies Inc (OTCPK:NSTGQ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0F1:Germany

Address

530 Fairview Avenue North, Seattle, WA, USA, 98109

Website

https://www.nanostring.com

NanoString Technologies Inc is engaged in the development, manufacturing and commercialization of instruments, consumables, and services for efficiently profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. Its core technology includes proprietary chemistries that enable the labeling and counting of single molecules. The firm uses its technology to develop tools for scientific and clinical research, primarily in the fields of genomics and proteomics. It offers two product platforms such as nCounter Analysis System or nCounter, and GeoMx Digital Spatial Profiler or DSP system both include instruments, related consumables, and software. NanoString Technologies generates revenue from the sale of products and related services and collaborations.

Executives

Jonathan Todd Garland	officer: Chief Commercial Officer	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
K Thomas Bailey	officer: Chief Financial Officer	1618 STATION STREET, VANCOUVER A1 V6A 1B6
R Bradley Gray	director, officer: President and CEO	530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
William Young	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waite Charles P Jr	director, 10 percent owner	11023 NE 116TH STREET, KIRKLAND WA 98034
Gregory Norden	director	16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Elisha W Finney	director	C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Teresa M. Foy	director	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Joseph M Beechem	officer: SVP, Research & Development	530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
John D. Gerace	officer: Chief Commercial Officer	C/O NANOSTRING TECHNOLOGIES, INC., 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Kirk Malloy	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
J. Chad Brown	officer: SVP, Sales & Marketing	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Robert Hershberg	director	3005 FIRST AVENUE, SEATTLE WA 98121
Janet George	director	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Dana E. Rollison	director	530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109